6.10.19 | Policy SWHR Provides Input on ICER Value Assessment Framework
SWHR provided input to the Institute for Clinical and Economic Review (ICER) on the 2020 update to its value assessment […]
5.20.19 | Policy Determining the Value of New Therapies: ICER Explores the Role of Real-World Evidence
Women won’t benefit from new therapies unless they can access them, and patient access to new innovations is based, in part, on value assessment.
4.15.19 | Policy SWHR Calls for Robust NIH Funding for FY 2020
SWHR sent letters to the Senate and House subcommittees that oversee funding for the National Institutes of Health (NIH) urging […]
3.19.19 | Policy SWHR Comments on HHS Task Force Pain Management Draft Report
SWHR sent comments to the U.S. Department of Health and Human Services (HHS) in response to the Pain Management Best […]
2.21.19 | Policy SWHR Principles Addressing Disparities in Drug Development
SWHR developed a set of principles to address diversity within the Patient-Focused Drug Development (PFDD) Program. The PFDD Program, housed […]
2.14.19 | Policy SWHR Input on NICHD Strategic Plan for FY2020-2024
SWHR sent a letter to Dr. Diana W. Bianchi, Director of the Eunice Kennedy Shriver National Institute of Child Health […]
1.31.19 | Policy SWHR Expresses Concerns About CMS Guidance for Next Generation Sequencing
In a letter to Centers for Medicare & Medicaid Services (CMS) Administrator Seema Verma, SWHR expressed concern about CMS’ new […]
1.25.19 | Sleep SWHR Response to NHLBI Women’s Health Working Group
SWHR responded to the National Heart, Lung, and Blood Institute (NHLBI) Women’s Health Working Group (WHWG) request for information regarding […]
1.22.19 | Policy SWHR Supports Women’s Health Research Day Resolution
SWHR released a letter of support sent to both Sen. Tammy Duckworth (D-IL) and Rep. Jan Schakowsky (D-IL-09) in acknowledgment […]
1.14.19 | Policy SWHR Engages With FDA on Patient-Focused Drug Development
SWHR seeks to ensure that meaningful input from women is included in the development and regulatory review of new medical products.
